Aleniglipron + Placebo
Phase 2Recruiting 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Obese
Conditions
Obese, Obesity, Obesity Type 2 Diabetes Mellitus, Weight Loss
Trial Timeline
Dec 1, 2025 → Nov 1, 2026
NCT ID
NCT07400588About Aleniglipron + Placebo
Aleniglipron + Placebo is a phase 2 stage product being developed by Structure Therapeutics for Obese. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07400588. Target conditions include Obese, Obesity, Obesity Type 2 Diabetes Mellitus.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07400588 | Phase 2 | Recruiting |
Competing Products
9 competing products in Obese
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lorcaserin | Eisai | Phase 1 | 33 |
| Bardoxolone methyl + Placebo | Kyowa Kirin | Phase 1 | 33 |
| LIK066 + Placebo | Novartis | Phase 2 | 52 |
| Investigational new drug company code: BGS649 + Placebo | Novartis | Phase 2 | 52 |
| Placebo + CT-388 | Roche | Phase 2 | 52 |
| Growth hormone treatment | Pfizer | Pre-clinical | 22 |
| BMS-963272 + Placebo | Bristol Myers Squibb | Phase 1 | 32 |
| ALN-4324 + Placebo | Alnylam Pharmaceuticals | Phase 1/2 | 38 |
| CRB-913 + Placebo | Corbus Pharmaceuticals | Phase 1 | 25 |
Other Products from Structure Therapeutics
aleniglipron or placebo + aleniglipron or placebo + aleniglipron or placebo + aleniglipron or placeboPhase 2
47
aleniglipron or placeboPhase 2
47
Aleniglipron or Placebo + Aleniglipron or Placebo + Aleniglipron or Placebo + Aleniglipron + Aleniglipron + Aleniglipron + AleniglipronPhase 2
47
GSBR-1290 + PlaceboPhase 1/2
36
GSBR-1290 (Capsule/Tablet) + GSBR-1290 + Placebo + Placebo (Capsule/Tablet)Phase 1
28